Last updated: 2026-09-16 13:20:20. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
NextCure, Inc. (NXTC) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $6.56, with a market capitalisation of $30.39M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $1.55 to $15.74. This page covers its latest market performance, valuation, price trends and company information.
$30.39M | |
$6.52 | |
$1,308.00 | |
$1.55 | |
$6.37 | |
317.00 | |
2.15M | |
-- | |
$15.74 | |
$1.55 | |
-- | |
-- |
NextCure, Inc. (NXTC) is trading at $6.56 in pre-market trading as of 2026-09-16 13:14:00, up 2.98% ($0.19) from the previous close of $6.37
Pre-market trading shows how investors are pricing NXTC before the regular session opens. The current pre-market price is above the previous close, indicating positive early trading sentiment.
Over the past seven days, NextCure, Inc. (NXTC) moved from $7.82 to $6.56, representing a decline of 16.11% ($1.26).
The stock traded between $6.06 and $8.64 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 88.33 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 35.3%
NXTC is currently trading at $6.56, placing it 35.3% of the way from its 52-week low of $1.55 to its 52-week high of $15.74. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
NextCure Inc is a clinical-stage biopharmaceutical company that is focused on advancing inventive medicines that treat cancer patients that do not respond to, or that have disease progression on, current therapies, through the use of targeted therapies including antibody-drug conjugates. The company's product candidates include NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer's disease.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 40 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of NextCure, Inc. (NXTC) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.